cardizem
| Product dosage: 120mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.44 | $43.08 (0%) | 🛒 Add to cart |
| 60 | $1.07 | $86.17 $64.12 (26%) | 🛒 Add to cart |
| 90 | $0.96 | $129.25 $86.17 (33%) | 🛒 Add to cart |
| 120 | $0.89 | $172.33 $107.21 (38%) | 🛒 Add to cart |
| 180 | $0.83 | $258.50 $150.29 (42%) | 🛒 Add to cart |
| 270 | $0.79 | $387.75 $214.42 (45%) | 🛒 Add to cart |
| 360 | $0.77
Best per pill | $517.00 $278.54 (46%) | 🛒 Add to cart |
| Product dosage: 180mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.24 | $67.13 (0%) | 🛒 Add to cart |
| 60 | $1.44 | $134.26 $86.17 (36%) | 🛒 Add to cart |
| 90 | $1.17 | $201.39 $105.20 (48%) | 🛒 Add to cart |
| 120 | $1.04 | $268.52 $124.24 (54%) | 🛒 Add to cart |
| 180 | $0.90 | $402.78 $162.31 (60%) | 🛒 Add to cart |
| 270 | $0.81 | $604.17 $217.42 (64%) | 🛒 Add to cart |
| 360 | $0.76
Best per pill | $805.56 $274.53 (66%) | 🛒 Add to cart |
Cardizem, known generically as diltiazem, is a calcium channel blocker primarily prescribed for managing cardiovascular conditions such as hypertension, chronic stable angina, and certain arrhythmias like atrial fibrillation. It functions by inhibiting calcium ion influx across cardiac and vascular smooth muscle cell membranes, leading to coronary and peripheral vasodilation, reduced myocardial oxygen demand, and slowed atrioventricular nodal conduction. Available in immediate-release, extended-release, and intravenous formulations, Cardizem is a cornerstone therapy in cardiology due to its efficacy and relatively favorable side effect profile compared to other antianginal and antihypertensive agents.
1. Introduction: What is Cardizem? Its Role in Modern Medicine
Cardizem, the brand name for diltiazem hydrochloride, belongs to the benzothiazepine class of calcium channel blockers. It is a mainstay in cardiovascular pharmacotherapy, addressing conditions stemming from increased vascular resistance and myocardial ischemia. Clinicians frequently turn to Cardizem for its dual ability to manage blood pressure and control heart rate, making it versatile in treating hypertensive patients with concomitant arrhythmias. Its development marked a significant advancement over older vasodilators by offering targeted action with fewer reflex tachycardic responses, thus cementing its role in evidence-based treatment guidelines from organizations like the American Heart Association.
2. Key Components and Bioavailability Cardizem
The active pharmaceutical ingredient in Cardizem is diltiazem hydrochloride, formulated to optimize absorption and duration of action. Bioavailability varies by formulation: immediate-release capsules exhibit approximately 40% absorption due to first-pass metabolism, while extended-release formulations are engineered to provide steady plasma concentrations over 24 hours, enhancing compliance and therapeutic consistency. The molecule’s pharmacokinetics are influenced by cytochrome P450 3A4 metabolism, necessitating consideration in patients on concomitant medications like statins or antifungals. Advanced delivery systems, such as the Geomatrix technology in some branded versions, allow for biphasic release—initial rapid absorption followed by sustained release—mimicking twice-daily dosing with a single tablet.
3. Mechanism of Action Cardizem: Scientific Substantiation
Cardizem exerts its effects by selectively blocking L-type calcium channels in vascular smooth muscle and cardiac cells. This inhibition prevents calcium entry, which is crucial for muscle contraction and pacemaker activity. In vascular beds, reduced calcium influx leads to vasodilation, decreasing systemic vascular resistance and afterload—key in hypertension management. In the heart, diltiazem preferentially affects the sinoatrial and atrioventricular nodes, slowing conduction velocity and increasing refractory period duration, which is therapeutic in supraventricular tachycardias. Unlike dihydropyridine calcium blockers, Cardizem has modest negative inotropic effects, making it suitable for patients with preserved ejection fraction but necessitating caution in heart failure with reduced EF.
4. Indications for Use: What is Cardizem Effective For?
Cardizem for Hypertension
Cardizem is a first-line agent for essential hypertension, particularly in patients with comorbidities like diabetes or renal impairment, where beta-blockers may be less desirable. Its vasodilatory effects reduce diastolic and systolic pressures without significantly impacting lipid or glucose metabolism.
Cardizem for Chronic Stable Angina
By dilating coronary arteries and reducing myocardial oxygen demand through decreased heart rate and contractility, Cardizem alleviates angina symptoms. It is often combined with nitrates or beta-blockers, though careful monitoring is required to avoid excessive bradycardia.
Cardizem for Atrial Fibrillation and Flutter
Cardizem is pivotal in rate control for atrial fibrillation, especially in acute settings via intravenous administration. It rapidly slows ventricular response, improving hemodynamic stability and symptoms like palpitations and dyspnea.
Cardizem for Vasospastic Angina
For Prinzmetal’s angina, characterized by coronary artery spasm, Cardizem’s direct vasodilatory action prevents spasms, reducing episode frequency and severity.
5. Instructions for Use: Dosage and Course of Administration
Dosing must be individualized based on indication, formulation, and patient response. Below is a general guide:
| Indication | Formulation | Initial Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|---|
| Hypertension | Extended-Release | 120–240 mg once daily | 120–540 mg once daily | Swallow whole; avoid crushing |
| Chronic Stable Angina | Immediate-Release | 30 mg 3–4 times daily | 180–360 mg daily in divided doses | With meals to reduce GI upset |
| Atrial Fibrillation (IV) | Intravenous | 0.25 mg/kg over 2 min | 5–15 mg/h infusion | Monitor ECG and BP continuously |
| Elderly/Hepatic Impairment | Any | 50% of standard dose | Titrate slowly | Assess renal function periodically |
Common side effects include headache, dizziness, edema, and bradycardia. Patients should be advised to avoid grapefruit juice, which inhibits CYP3A4 and can elevate diltiazem levels.
6. Contraindications and Drug Interactions Cardizem
Cardizem is contraindicated in patients with sick sinus syndrome (except with functioning pacemaker), second- or third-degree AV block, hypotension, and acute myocardial infarction with pulmonary congestion. Caution is warranted in heart failure with reduced ejection fraction, as negative inotropy may exacerbate symptoms.
Significant drug interactions occur with:
- Beta-blockers: Increased risk of bradycardia and heart block.
- Statins (simvastatin, lovastatin): Elevated statin levels raising rhabdomyolysis risk.
- Digoxin: Increased digoxin concentrations; monitor levels.
- Cyclosporine: Reduced metabolism potentiating nephrotoxicity.
Pregnancy category C: use only if benefit justifies potential fetal risk.
7. Clinical Studies and Evidence Base Cardizem
The efficacy of Cardizem is supported by numerous trials. The DAVIT II study demonstrated reduced reinfarction and mortality post-MI in patients without heart failure. In hypertension, the VALUE trial underscored its non-inferiority to valsartan in preventing cardiac events. For atrial fibrillation, the AFFIRM trial established rate control with drugs like diltiazem as equivalent to rhythm control for mortality outcomes. A 2018 meta-analysis in Journal of the American College of Cardiology confirmed that calcium channel blockers, including Cardizem, reduce stroke risk more effectively than beta-blockers in hypertensive patients.
8. Comparing Cardizem with Similar Products and Choosing a Quality Product
Cardizem is often compared to other calcium channel blockers like amlodipine (dihydropyridine) and verapamil (non-dihydropyridine). Amlodipine offers stronger peripheral vasodilation with minimal cardiac effects, making it preferable for isolated hypertension, while Cardizem provides superior heart rate control. Verapamil has more pronounced negative inotropy and constipation side effects. When selecting, consider:
- Formulation needs: Extended-release for compliance.
- Comorbidities: Cardizem for AF with hypertension.
- Generic vs. brand: Bioequivalence studies support generics, but check for consistent release technology.
9. Frequently Asked Questions (FAQ) about Cardizem
What is the recommended course of Cardizem to achieve results?
Therapeutic effects for hypertension or angina are typically seen within 2 weeks, but full stabilization may take 4–6 weeks. Continuous use is necessary for chronic conditions.
Can Cardizem be combined with beta-blockers?
Yes, but with extreme caution due to additive bradycardic effects. Monitor heart rate and AV conduction regularly.
Is Cardizem safe in elderly patients?
Yes, but initiate at lower doses due to reduced clearance and increased sensitivity to hypotensive effects.
Does Cardizem cause weight gain?
No, significant weight gain is uncommon; peripheral edema is a frequent side effect but is not true weight gain from fluid retention.
10. Conclusion: Validity of Cardizem Use in Clinical Practice
Cardizem remains a validated, effective option in cardiovascular therapy, balancing efficacy with a manageable side effect profile. Its versatility across hypertension, angina, and arrhythmias, backed by robust clinical data, ensures its continued relevance. Healthcare providers should individualize therapy, considering contraindications and interactions, to optimize patient outcomes.
I remember when we first started using Cardizem extensively in our clinic back in the late 90s—we were transitioning from older vasodilators and the learning curve was steep. Had this one patient, Frank, 68-year-old with long-standing hypertension and new-onset atrial fib. We started him on Cardizem CD 180 mg, but he came back two weeks later with fatigue and HR down to 48. Our team was divided—cardiologist wanted to push through, I argued for dose reduction. We compromised, dropped to 120 mg, added a low-dose ARB. Took another month to stabilize, but Frank’s been controlled now for over a decade, still sends Christmas cards. What surprised me was how his exercise tolerance improved more than we expected—the vasodilation probably helped his peripheral circulation more than we accounted for in the trials. Another case, Sarah, 52 with vasospastic angina—classic early morning chest pain. Cardizem worked within days where nitrates had failed. But we learned the hard way about the grapefruit interaction with her husband’s statin—had to switch him to pravastatin. These real-world nuances never make it into the package insert. Follow-ups over years show most patients tolerate it well if we start low, go slow. Mrs. Gable, 81, been on it 15 years for hypertension, says it “keeps her steady” without the cough she had with ACE inhibitors. That’s the stuff they don’t teach in pharmacology—the longitudinal relationship with a medication. We’ve had our share of failures too—patients who developed edema couldn’t tolerate it, or those where it just didn’t control their AF adequately. But overall, it’s been one of our workhorses. The key is remembering it’s not just about the calcium channels—it’s about the person taking it.